Funding
ALF, Alzheimer Drug Discovery Foundation, Dementia
NEURODEGENERATIVE DISEASE, ALZHEIMER
Open access funding provided by University of Cape Town. The study was funded by the European and Developing Countries Clinical Trials Partnership (EDCTP Grant number SP.2011.41304.065/BMBF01KA1306). LT was funded by the Discovery foundation. HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532), the European Research Council (#681712 and #101053962), Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer’s Association (#ADSF-21-831376-C, #ADSF-21-831381-C and #ADSF-21-831377-C), the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2019-0228), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), and the UK Dementia Research Institute at UCL (UKDRI-1003). MG received funding from the Swedish state under an agreement between the Swedish government and the county councils (ALF agreement ALFGBG-965885).